ALTUVOCT 1 000 IU powder and solvent for solution for injection

DRUG2 trials

Sponsors

Swedish Orphan Biovitrum AB (publ), GWT-Tud GmbH

Conditions

Congenital hemophilia A (HA)Haemophilia ASynovitis

Phase 3

Efanesoctocog alfa treatment in patients with synovitis in congenital hemophilia A: multicenter, randomized, open-label, phase 3 clinical trial

Not yet recruitingCTIS2025-523896-44-00

GWT-Tud GmbHCongenital hemophilia A (HA), Synovitis

Target: 60Updated: 2026-06-10

Phase 4

A low-interventional study to evaluate long-term effectiveness of real-world prophylactic treatment with efanesoctocog alfa on joint health in people with haemophilia A (ALTITUDE)

RecruitingCTIS2024-517812-31-00

Swedish Orphan Biovitrum AB (publ)Haemophilia A

Start: 2025-05-21Target: 175Updated: 2025-08-29